Part:BBa_K4165081
SPINK4 (Serine Peptidase Inhibitor Kazal type 4).
This basic part encodes Human serine protease inhibitor known as SPINK4 which is able to inhibit trypsin-like proteases, like HtrA1 (BBa_K4165004).
Usage and Biology
This type of family encodes for a type of inhibitor that is able to inhibit serine proteases and it is predicted to be located extracellularly. The inhibitor binds to trypsin proteases and since the catalytic core of HtrA1 (BBa_K4165004) is considered as a tyrpsin-like catalytic domain, so this inhibitor also is considered to inhibit the function of HtrA1 [1-4].
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 135
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 135
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 135
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 135
- 1000COMPATIBLE WITH RFC[1000]
Dry-Lab Charachtarization
Modelling
Figure 1.: A graphical illustration showing the structure of the inhibitor (Model 2-RosettaFold).
Docking
Gibbs Free energy = -25.635
Figure 2.: A graphical illustration showing the binding of the inhibitor with HtrA1 protein (ClusPro).
References
1 - Frochaux, V., Hildebrand, D., Talke, A., Linscheid, M. W., & Schlüter, H. (2014). Alpha-1-antitrypsin: a novel human high temperature requirement protease A1 (HTRA1) substrate in human placental tissue. PloS one, 9(10), e109483.
2 - Grau, S., Baldi, A., Bussani, R., Tian, X., Stefanescu, R., Przybylski, M., ... & Ehrmann, M. (2005). Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proceedings of the National Academy of Sciences, 102(17), 6021-6026.
3 - Eigenbrot, C., Ultsch, M., Lipari, M. T., Moran, P., Lin, S. J., Ganesan, R., ... & Kirchhofer, D. (2012). Structural and functional analysis of HtrA1 and its subdomains. Structure, 20(6), 1040-1050.
4 - Chen, T. J., Tian, Y. F., Chou, C. L., Chan, T. C., He, H. L., Li, W. S., ... & Lai, H. Y. (2021). High spink4 expression predicts poor outcomes among rectal cancer patients receiving CCRT. Current Oncology, 28(4), 2373-2384.
| None |